IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: and Fc fragments inhibiting complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, which suggests that IdeS might be useful for desensitization. We report on the combined experience of two independently performed open-label, phase 1-2 trials (conducted in Sweden and the United States) that assessed the efficacy of IdeS with regard to desensitization and transplantation of a kidney from an HLA-incompatible donor. METHODS: We administered IdeS to 25 highly HLA-sensitized patients (11 patients in Uppsala or Stockholm, Sweden, and 14 in Los Angeles) before the transplantation of a kidney from an HLA-incompatible donor. Frequent monitoring for adverse events, outcomes, donor-specific antibodies, and renal function was performed, as were renal biopsies. Immunosuppression after transplantation consisted of tacrolimus, mycophenolate mofetil, and glucocorticoids. Patients in the U.S. study also received intravenous immune globulin and rituximab after transplantation to prevent antibody rebound. RESULTS: Recipients in the U.S. study had a significantly longer cold ischemia time (the time elapsed between procurement of the organ and transplantation), a significantly higher rate of delayed graft function, and significantly higher levels of class I donor-specific antibodies than those in the Swedish study. A total of 38 serious adverse events occurred in 15 patients (5 events were adjudicated as being possibly related to IdeS). At transplantation, total IgG and HLA antibodies were eliminated. A total of 24 of 25 patients had perfusion of allografts after transplantation. Antibody-mediated rejection occurred in 10 patients (7 patients in the U.S. study and 3 in the Swedish study) at 2 weeks to 5 months after transplantation; all these patients had a response to treatment. One graft loss, mediated by non-HLA IgM and IgA antibodies, occurred. CONCLUSIONS: IdeS reduced or eliminated donor-specific antibodies and permitted HLA-incompatible transplantation in 24 of 25 patients. (Funded by Hansa Medical; ClinicalTrials.gov numbers, NCT02224820 , NCT02426684 , and NCT02475551 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, IdeS is an endopeptidase able to degrade circulating IgG that is currently being tested in transplant patients (123).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global burden of group A streptococcal diseases
Carapetis, J. R., Steer, A. C., Mulholland, E. K., & Weber, M. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70267-x · Cited by 2,998
Significance of the Positive Crossmatch Test in Kidney Transplantation
Patel, R., & Terasaki, P. I. (1969) · New England Journal of Medicine · doi:10.1056/nejm196904032801401 · Cited by 1,508
Haas, M., Sis, B., Racusen, L. C., Solez, K., Glotz, D., Colvin, R. B., Castro, M. C. R., David, D. S. R., David-Neto, E., Bagnasco, S. M., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12590 · Cited by 1,350 · cited 1×
“Scoring of various values (complement factor 4d deposition [C4d+], interstitial fibrosis and tubular atrophy [IFTA], glomerulitis plus peritubular capillaritis [GPC], transplant glomerulopathy [TG], and thrombotic microangiopathy [TMA]) was based on Banff 2013 criteria.(18) T bars indicate 1 SD.”
MethodSelf-citationThe Quality of Life of Patients with End-Stage Renal Disease
Evans, R. W., Manninen, D. L., Garrison, L. P., Hart, L. G., Blagg, C. R., Gutman, R. A., Hull, A. R., & Lowrie, E. G. (1985) · New England Journal of Medicine · doi:10.1056/nejm198502283120905 · Cited by 1,183
Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival
Loupy, A., Lefaucheur, C., Vernerey, D., Prugger, C., van Huyen, J.-P. D., Mooney, N., Suberbielle, C., Frémeaux-Bacchi, V., Méjean, A., Desgrandchamps, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302506 · Cited by 852
Comparison of Survival Probabilities for Dialysis Patients vs Cadaveric Renal Transplant Recipients
Port, F. K. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510110079036 · Cited by 825
Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney Transplantation
Lefaucheur, C., Loupy, A., Hill, G. S., Andrade, J., Nochy, D., Antoine, C., Gautreau, C., Charron, D., Glotz, D., & Suberbielle-Boissel, C. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009101065 · Cited by 789
Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
Vo, A. A., Lukovsky, M., Toyoda, M., Wang, J., Reinsmoen, N. L., Lai, C.-H., Peng, A., Villicana, R., & Jordan, S. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707894 · Cited by 692
Self-citationDesensitization in HLA-Incompatible Kidney Recipients and Survival
Montgomery, R. A., Lonze, B. E., King, K. E., Kraus, E. S., Kucirka, L. M., Locke, J. E., Warren, D. S., Simpkins, C. E., Dagher, N. N., Singer, A. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012376 · Cited by 687
IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G
von Pawel-Rammingen, U. (2002) · The EMBO Journal · doi:10.1093/emboj/21.7.1607 · Cited by 473
Research works printed but not linked: 1
- 12. ies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398406.
Cited by
Velleca, A., Shullo, M. A., Dhital, K., Azeka, E., Colvin, M., DePasquale, E., Farrero, M., García-Guereta, L., Jamero, G., Khush, K., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.10.015 · Cited by 645
Antibody-Mediated Rejection of Solid-Organ Allografts
Loupy, A., & Lefaucheur, C. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1802677 · Cited by 549
Schinstock, C. A., Mannon, R. B., Budde, K., Chong, A. S., Haas, M., Knechtle, S., Lefaucheur, C., Montgomery, R. A., Nickerson, P., Tullius, S. G., et al. (2020) · Transplantation · doi:10.1097/tp.0000000000003095 · Cited by 345
“Imlifidase (Hansa Biopharma AB), an IgG-degrading enzyme of Streptococcus pyogenes (IdeS), can rapidly reduce or even eliminate anti-HLA DSA and is undergoing clinical trials in AMR.(84) IdeS cleaves human IgG at a highly specific amino acid sequence within the hinge region producing Fc and F(ab)2 fragments and effect…”
BackgroundSelf-citationLeborgne, C., Barbon, E., Alexander, J. M., Hanby, H., Delignat, S., Cohen, D. M., Collaud, F., Muraleetharan, S., Lupo, D., Silverberg, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0911-7 · Cited by 336
Pilch, N. A., Bowman, L. J., & Taber, D. J. (2021) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2481 · Cited by 184
Drug delivery systems for CRISPR-based genome editors
Madigan, V., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 172
Montgomery, R. A., Tatapudi, V. S., Leffell, M. S., & Zachary, A. A. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0039-x · Cited by 171
Yazdani, S., Callemeyn, J., Gazut, S., Lerut, E., de Loor, H., Wevers, M., Heylen, L., Saison, C., Koenig, A., Thaunat, O., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.08.027 · Cited by 166
“, by B cell–depleting rituximab treatment), plasma cell inactivation (by proteasome inhibition using bortezomib), or HLA antibody depletion by plasma exchange or the IgG-degrading enzyme derived from Streptococcus pyogenes has been tested in clinical studies.(7) However, most of these therapies had only limited succes…”
MethodAntibody-mediated rejection: New approaches in prevention and management
Montgomery, R. A., Loupy, A., & Segev, D. L. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14584 · Cited by 162
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
Kwun, J., Matignon, M., Manook, M., Guendouz, S., Audard, V., Kheav, V., Poullot, E., Gautreau, C., Ezekian, B., Bodez, D., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018121254 · Cited by 149
Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme
Elmore, Z. C., Oh, D. K., Simon, K. E., Fanous, M. M., & Asokan, A. (2020) · JCI Insight · doi:10.1172/jci.insight.139881 · Cited by 137
“Furthermore, previous work (27) had patients immunosuppressed after transplantation, which was well after IdeS administration.”
Intestinal Permeability and IgA Provoke Immune Vasculitis Linked to Cardiovascular Inflammation
Noval Rivas, M., Wakita, D., Franklin, M. K., Carvalho, T. T., Abolhesn, A., Gomez, A. C., Fishbein, M. C., Chen, S., Lehman, T. J., Sato, K., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.05.021 · Cited by 131
“Recently, IgG endopeptidase treatment has been successfully used to block donor pathogenic IgG and complement activation in sensitized renal transplant patients (Jordan et al., 2017).”
BackgroundSchulz, M., Levy, D. I., Petropoulos, C. J., Bashirians, G., Winburn, I., Mahn, M., Somanathan, S., Cheng, S. H., & Byrne, B. J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.010 · Cited by 125
Jordan, S. C., Legendre, C. M., Desai, N. M., Lorant, T., Bengtsson, M., Lonze, B. E., Vo, A. A., Runström, A., Laxmyr, L., Sjöholm, K., et al. (2020) · Transplantation · doi:10.1097/tp.0000000000003496 · Cited by 123
“Postdose, patients received high-dose IVIg 10% solution 2g/kg BW (max 140 g for patients >70 kg) 7 d after imlifidase infusion and rituximab (anti-CD20) 1 g IV 9 d after imlifidase infusion (Figure 1).(21)”
MethodSelf-citationLonze, B. E., Tatapudi, V., Weldon, E. P., Min, E. S., Ali, N. M., Deterville, C. L., Gelb, B. E., Benstein, J. A., Dagher, N. N., Wu, M. T., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002924 · Cited by 117
The therapeutic challenge of late antibody‐mediated kidney allograft rejection
Böhmig, G. A., Eskandary, F. A., Doberer, K., & Halloran, P. F. (2019) · Transplant International · doi:10.1111/tri.13436 · Cited by 126
“not be able to considerably affect rebound antibody responses: first studies on the use of IdeS as a pretransplant desensitization treatment have shown that, despite effective IgG elimination, a significant proportion of treated patients developed rejection, which was attributed to a rapid rebound of antibody [85,86].”
BackgroundBouquegneau, A., Lohéac, C., Aubert, O., Bouatou, Y., Viglietti, D., Empana, J. P., Ulloa, C., Murad, M. H., Legendre, C. M., Glotz, D., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002572 · Cited by 123
Lorant, T., Bengtsson, M., Eich, T., Eriksson, B.-M., Winstedt, L., Järnum, S., Stenberg, Y., Robertson, A.-K., Mosén, K., Björck, L., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14733 · Cited by 108
Self-citationLefaucheur, C., Louis, K., Morris, A. B., Taupin, J., Nickerson, P. W., Tambur, A. R., Gebel, H. M., Reed, E. F., KOBASHIGAWA, J. A., Chandraker, A. K., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2022.11.013 · Cited by 116
Sialylation as an Important Regulator of Antibody Function
Vattepu, R., Sneed, S. L., & Anthony, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.818736 · Cited by 118
The multifaceted role of complement in kidney transplantation
Biglarnia, A., Huber-Lang, M. S., Mohlin, C., Ekdahl, K. N., & Nilsson, B. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0071-x · Cited by 105
Glotz, D., Russ, G. R., Rostaing, L. P. E., Legendre, C. M., Tufveson, G., Chadban, S. J., Grinyo, J. M., Mamode, N., Rigotti, P., Couzi, L., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15397 · Cited by 95
Self-citationSchinstock, C. A., Smith, B. H., Montgomery, R. A., Jordan, S. C., Bentall, A., Mai, M., Khamash, H. A., & Stegall, M. D. (2019) · Clinical Transplantation · doi:10.1111/ctr.13751 · Cited by 95
Self-citationOutcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients
Kjellman, C., Maldonado, A. Q., Sjöholm, K., Lonze, B. E., Montgomery, R. A., Runström, A., Lorant, T., Desai, N. M., Legendre, C. M., Lundgren, T., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16754 · Cited by 95
Self-citationRecent Advances and Clinical Outcomes of Kidney Transplantation
Thongprayoon, C., Hansrivijit, P., Leeaphorn, N., Acharya, P. C., Torres‐Ortiz, A., Kaewput, W., Kovvuru, K. R., Kanduri, S. R., Bathini, T. J., & Cheungpasitporn, W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041193 · Cited by 108
“Recent studies have been conducted aimed at preventing or treating ABMR [16,17].”
BackgroundMethodInfluentialMamode, N., Bestard, O., Claas, F. H. J., Furian, L., Griffin, S., Legendre, C. M., Pengel, L. H. M., & Naesens, M. (2022) · Transplant International · doi:10.3389/ti.2022.10511 · Cited by 91
“It cleaves all IgGs, both intra- and extra-vascularly, without regard to their specificity, with an immediate action that lasts around 5–7 days; this drug cannot be re-dosed due to immunogenicity (56).”
Monahan, P. E., Négrier, C., Tarantino, M., Valentino, L. A., & Mingozzi, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112471 · Cited by 85
Evading and overcoming AAV neutralization in gene therapy
Earley, J., Piletska, E. V., Ronzitti, G., & Piletsky, S. A. (2022) · Trends in biotechnology · doi:10.1016/j.tibtech.2022.11.006 · Cited by 93
Anti-glomerular basement membrane disease: an update on subgroups, pathogenesis and therapies
Segelmark, M., & Hellmark, T. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy327 · Cited by 80
Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation
Ziemann, M., Altermann, W., Angert, K., Arns, W., Bachmann, A., Bakchoul, T., Banas, B., von Borstel, A., Budde, K., Ditt, V., et al. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.13401118 · Cited by 76
“ofmismatches forHLA-A/B/DR 3 (2–4) 4 (3–5) 4 (3–5) 133 3 (2–4) 3 (2–4) 3 (3–4) 1 Induction therapy, n (%) 164 255 None 177 (17) 7 (13) 3 (6) 308 (13) 13 (9) 5 (4) ATG 62 (6) 8 (14) 11 (23) 410 (18) 41 (29) 48 (42) IL-2 671 (63) 29 (52) 16 (34) 1538 (67) 77 (54) 41 (36) CD20 15 (1) 0 (0) 4 (9) 2 (0) 1 (1) 0 (0) CD52 0…”
BackgroundBurghuber, C. K., Manook, M., Ezekian, B., Gibby, A., Leopardi, F. V., Song, M., Jenks, J. A., Saccoccio, F. M., Permar, S. R., Farris, A. B., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.15067 · Cited by 78
tRNA therapeutics for genetic diseases
Coller, J., & Ignatova, Z. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00829-9 · Cited by 76
Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review
Kant, S., Kronbichler, A., Sharma, P., & Geetha, D. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.07.019 · Cited by 78
“It is being investigated (as imlifidase) in the management of highly sensitized kidney transplant recipients because it eliminates donor-specific antibodies and enables human leukocyte antigen–incompatible kidney transplantation.(8)”
BackgroundImlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation
Huang, E., Maldonado, A. Q., Kjellman, C., & Jordan, S. C. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16828 · Cited by 70
Self-citationUhlin, F., Szpirt, W. M., Kronbichler, A., Bruchfeld, A. N., Soveri, I., Rostaing, L. P. E., Daugas, É., Lionet, A., Kamar, N., Rafat, C., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021111460 · Cited by 69
Self-citationSummary of 2017 FDA Public Workshop: Antibody-mediated Rejection in Kidney Transplantation
Velidedeoğlu, E., Cavaillé-Coll, M. W., Bala, S., Belen, O., Wang, Y., & Albrecht, R. (2018) · Transplantation · doi:10.1097/tp.0000000000002141 · Cited by 79
Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives
Schrezenmeier, E. V., Jayne, D. R. W., & Dörner, T. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017040367 · Cited by 74
Marchetti, M., Zermatten, M. G., Calderara, D. B., Aliotta, A., & Alberio, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040683 · Cited by 65
Crespo-Leiro, M. G., Costanzo, M. R., Gustafsson, F., Khush, K. K., Macdonald, P. S., Potena, L., Stehlik, J., Zuckermann, A. O., & Mehra, M. R. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac204 · Cited by 70
Gross, D., Tedesco, N., Leborgne, C., & Ronzitti, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857276 · Cited by 66
Heart Transplant Immunosuppression Strategies at Cedars-Sinai Medical Center
Chang, D., Youn, J., Dilibero, D., Patel, J. K., & KOBASHIGAWA, J. A. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2020.0034 · Cited by 62
Schmitz, R., Fitch, Z. W., Schroder, P. M., Choi, A. Y., Manook, M., Yoon, J., Song, M., Yi, J. S., Khandelwal, S., Arepally, G. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25745-7 · Cited by 63
Engineering immune-evasive allogeneic cellular immunotherapies
Martin, K. E., Hammer, Q., Perica, K., Sadelain, M., & Malmberg, K. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01022-8 · Cited by 69
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
“Similarly, IdeS is an endopeptidase able to degrade circulating IgG that is currently being tested in transplant patients (123).”
BackgroundRecent advances in kidney transplantation: a viewpoint from the Descartes advisory board*
Abramowicz, D., Oberbauer, R. W., Heemann, U. W., Viklický, O., Peruzzi, L., Mariat, C., Crespo, M., Budde, K., & Oniscu, G. C. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx365 · Cited by 57
Outstanding questions in transplantation: B cells, alloantibodies, and humoral rejection
Chong, A. S., Rothstein, D. M., Safa, K., & Riella, L. V. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15323 · Cited by 57
Translating B cell immunology to the treatment of antibody-mediated allograft rejection
Heeger, P. S., Carrera-Haro, M. A., & Jordan, S. C. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00791-0 · Cited by 60
Self-citationAntibody-mediated rejection: prevention, monitoring and treatment dilemmas
Rodríguez‐Ramírez, S., Jurdi, A. A., Konvalinka, A., & Riella, L. V. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001011 · Cited by 56
“imilfidase) [91], newer generation antiCD20 antibodies (e.”
Humoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis
Gollomp, K. L., Sarkar, A., Harikumar, S., Seeholzer, S. H., Arepally, G. M., Hudock, K. M., Rauova, L., Kowalska, M. A., & Poncz, M. (2019) · Blood · doi:10.1182/blood.2019002329 · Cited by 52
The past, present, and future of enzyme-based therapies
Hennigan, J. N., & Lynch, M. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.004 · Cited by 52
Clazakizumab for desensitization in highly sensitized patients awaiting transplantation
Vo, A. A., Huang, E., Ammerman, N., Toyoda, M., Ge, S., Haas, M., Zhang, X., Peng, A., Najjar, R., Williamson, S., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16926 · Cited by 54
Self-citationSoveri, I., Mölne, J., Uhlin, F., Nilsson, T., Kjellman, C., Sonesson, E., & Segelmark, M. (2019) · Kidney International · doi:10.1016/j.kint.2019.06.019 · Cited by 51
Self-citationEvolving Areas in Heart Transplantation
Weber, B., KOBASHIGAWA, J. A., & Givertz, M. M. (2017) · JACC Heart Failure · doi:10.1016/j.jchf.2017.10.009 · Cited by 49
Kardol‐Hoefnagel, T., & Otten, H. G. (2020) · Transplantation · doi:10.1097/tp.0000000000003551 · Cited by 48
“IdeS is an endopeptidase that cleaves all subclasses of human IgG and appears to be effective in DSA clearance in HLA-sensitized kidney transplant recipients.(114,115) Recently, 3 patients with anti-GBM disease were successfully treated with IdeS.”
BackgroundProtection of cell therapeutics from antibody-mediated killing by CD64 overexpression
Gravina, A., Tediashvili, G., Rajalingam, R., Quandt, Z., Deisenroth, C., Schrepfer, S., & Deuse, T. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01540-7 · Cited by 54
Current Approaches to Desensitization in Solid Organ Transplantation
Schinstock, C. A., Tambur, A. R., & Stegall, M. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686271 · Cited by 48
Leibler, C., Matignon, M., Moktefi, A., Samson, C., Zarour, A., Malard, S., Boutin, E., Pilon, C., Salomon, L., Natella, P.-A., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.15229 · Cited by 47
Alishetti, S., FARR, M. A., Jennings, D. L., Şerban, G., Uriel, N. Y., SAYER, G. T., Vasilescu, E. R., Restaino, S. W., Chong, A. S., & Habal, M. V. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16113 · Cited by 47
The curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 53
The Evolution of Lung Transplant Immunosuppression
Ivulich, S. P., Westall, G. P., Dooley, M. J., & Snell, G. I. (2018) · Drugs · doi:10.1007/s40265-018-0930-6 · Cited by 48
Memory B Cells and Long-lived Plasma Cells
Ionescu, L., & Urschel, S. (2019) · Transplantation · doi:10.1097/tp.0000000000002594 · Cited by 51
Liver‐directed gene therapy for inherited metabolic diseases
Baruteau, J., Brunetti‐Pierri, N., & Gissen, P. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12709 · Cited by 48
Adeno-associated virus–based gene therapy treats inflammatory kidney disease in mice
Wu, G., Liu, S., Hagenstein, J., Alawi, M., Hengel, F. E., Schaper, M., Akyüz, N., Liao, Z., Wanner, N., Tomas, N. M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174722 · Cited by 48
Kizlik‐Masson, C., Deveuve, Q., Zhou, Y., Vayne, C., Thibault, G., McKenzie, S. E., Pouplard, C., Loyau, S., Gruel, Y., & Rollin, J. (2019) · Blood · doi:10.1182/blood.2019000437 · Cited by 44
Couzi, L., Malvezzi, P., Amrouche, L., Anglicheau, D., Blancho, G., Caillard, S., Freist, M., Guidicelli, G. L., Kamar, N., Lefaucheur, C., et al. (2023) · Transplant International · doi:10.3389/ti.2023.11244 · Cited by 43
“Four to 6 hours after Imlifidase infusion, the entire IgG pool is degraded into F(ab’)2 and Fc fragments [2].”
BackgroundResultInfluentialJordan, S. C., Ammerman, N., Choi, J., Huang, E., Peng, A., Sethi, S., Najjar, R., Kim, I. K., Toyoda, M., Kumar, S., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15913 · Cited by 46
Self-citationAntibody‐mediated rejection in xenotransplantation: Can it be prevented or reversed?
Habibabady, Z. A., McGrath, G., Kinoshita, K., Maenaka, A., Ileka, I., Elias, G. F., Zaletel, T., Rosales, I. A., Hara, H., Pierson, R. N., et al. (2023) · Xenotransplantation · doi:10.1111/xen.12816 · Cited by 43
Transplanting the Untransplantable
Holscher, C. M., Jackson, K. R., & Segev, D. L. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.04.025 · Cited by 42
Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Verdera, H. C., Unzu, C., Valeri, E., Adriouch, S., González‐Aseguinolaza, G., Mingozzi, F., & Kajaste‐Rudnitski, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.119 · Cited by 47
Ge, S., Chu, M., Choi, J., Louie, S., Vo, A. A., Jordan, S. C., & Toyoda, M. (2019) · Transplantation · doi:10.1097/tp.0000000000003023 · Cited by 40
“We have recently reported on the results of 2 independently conducted open-label and phase 1–2 trials assessing the safety and efficacy of IdeS as a desensitization agent in 25 HLA-sensitized (HS) kidney transplant patients.(12) In this study, we showed that the concentration of serum IgG including DSA became nearly 0…”
MethodResultSelf-citationComplement Activation by Adeno-Associated Virus-Neutralizing Antibody Complexes
West, C., Federspiel, J. D., Rogers, K., Khatri, A., Rao-Dayton, S., Ocana, M. F., Lim, S., D'Antona, A. M., Casinghino, S., & Somanathan, S. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.018 · Cited by 39
Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective
Schwartze, J. T., Havenga, M. J. E., Bakker, W. A. M., Bradshaw, A. C., & Nicklin, S. A. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02208-0 · Cited by 46
IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation
Woodle, E. S., Tremblay, S., & Driscoll, J. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1711335 · Cited by 39
Jouvé, T., Laheurte, C., Noble, J., Weinhard, J., Daligault, M., Renaudin, A., Bennani, H. N., Masson, D., Gravelin, E., Bugnazet, M., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16709 · Cited by 38
Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization
Choi, A. Y., Manook, M., Olaso, D., Ezekian, B., Park, J. B., Freischlag, K., Jackson, A. M., Knechtle, S. J., & Kwun, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694763 · Cited by 39
Gene therapy for genetic diseases: challenges and future directions
Beibei, Q. I. E., Tuo, J., Chen, F., Ding, H., & Lyu, L. (2025) · MedComm · doi:10.1002/mco2.70091 · Cited by 45
The role of complement in antibody mediated transplant rejection
Thurman, J. M., Panzer, S. E., & Quintrec, M. L. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.06.002 · Cited by 45
“This agent was tested in 25 highly sensitized recipients prior to transplantation with HLA-incompatible allografts (Jordan et al., 2017).”
BackgroundAl-Salama, Z. T. (2020) · Drugs · doi:10.1007/s40265-020-01418-5 · Cited by 37
Ros‐Gañán, I., Hommel, M., Trigueros‐Motos, L., Tamarit, B., Rodríguez‐García, E., Salas, D., Pérez, G., Douar, A. M., Combal, J. P., Bénichou, B., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1375 · Cited by 38
Loo, L., Harris, S., Milton, M., Meena, M., Lembke, W., Berisha, F., Bertholet, S., Dessy, F. J., Dodge, R. W., Fang, X., et al. (2022) · Bioanalysis · doi:10.4155/bio-2022-0081 · Cited by 41
Daligault, M., Bardy, B., Noble, J., Bourdin, A., Masson, D., Bennani, H. N., Bugnazet, M., Malvezzi, P., Rostaing, L. P. E., & Jouvé, T. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001139 · Cited by 36
Klontz, E. H., Trastoy, B., Deredge, D. J., Fields, J. K., Li, C., Orwenyo, J., Marina, A., Beadenkopf, R., Günther, S., Flores, J., et al. (2019) · ACS Central Science · doi:10.1021/acscentsci.8b00917 · Cited by 35
Novel Therapeutic Approaches to Allosensitization and Antibody-mediated Rejection
Jordan, S. C., Ammerman, N., Choi, J., Huang, E., Peng, A., Sethi, S., Najjar, R., Toyoda, M., Lim, K., Louie, S., et al. (2018) · Transplantation · doi:10.1097/tp.0000000000002462 · Cited by 35
Self-citationDesensitization in Crossmatch-positive Kidney Transplant Candidates
Noble, J., Jouvé, T., Malvezzi, P., & Rostaing, L. P. E. (2022) · Transplantation · doi:10.1097/tp.0000000000004279 · Cited by 32
Mayer, K. A., Budde, K., Jilma, B., Doberer, K., & Böhmig, G. A. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2091131 · Cited by 32
Current Desensitization Strategies in Heart Transplantation
Habal, M. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702186 · Cited by 33
Torija, A., Matignon, M., Vincenti, F., Casanova‐Ferrer, F., Pilon, C., Tambur, A. R., Donadeu, L., Crespo, E., Kervella, D., Meneghini, M., et al. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.08.004 · Cited by 32
New Insights into the Pathogenesis and Treatment Strategies in IgA Nephropathy
Scionti, K., Molyneux, K., Selvaskandan, H., Barratt, J., & Cheung, C. K. (2021) · Glomerular Diseases · doi:10.1159/000519973 · Cited by 31
Detection and management of HLA sensitization in candidates for adult heart transplantation
DeFilippis, E. M., Kransdorf, E. P., Jaiswal, A., Zhang, X., Patel, J. K., KOBASHIGAWA, J. A., Baran, D. A., & Kittleson, M. M. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.12.019 · Cited by 29
Self-citationTransplantation in highly sensitized patients: challenges and recommendations
Heidt, S., & Claas, F. H. J. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1498335 · Cited by 28
“IdeS treatment resulted in a total loss of serum IgG within 6 h after administration, a time in which all patients became DSA negative [63].”
BackgroundFuture developments in kidney transplantation
Viklický, O., Novotny, M., & Hrubá, P. (2019) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000722 · Cited by 28
“IdeS was used as part of a desensitization regimen in a two single-centre open-label phase 1–2 trial in 2017 [21].”
MethodTransfusion-induced HLA sensitization in wait-list patients and kidney transplant recipients
Willicombe, M. K., & Roberts, D. J. (2024) · Kidney International · doi:10.1016/j.kint.2024.07.030 · Cited by 27
Cole, M., Ranjan, N., Gerber, G. F., Pan, X.-Z., Flores-Guerrero, D., McNamara, G. T., Chaturvedi, S., Sperati, C. J., McCrae, K. R., & Brodsky, R. A. (2024) · Blood · doi:10.1182/blood.2024025850 · Cited by 27
On the road to eliminating long‐lived plasma cells—“are we there yet?”
Markmann, C., & Bhoj, V. G. (2021) · Immunological Reviews · doi:10.1111/imr.13015 · Cited by 29
The Complement System in Kidney Transplantation
Santarsiero, D., & Aiello, S. (2023) · Cells · doi:10.3390/cells12050791 · Cited by 32
Chen, H., Hu, K., Tang, Q., Wang, J., Gu, Q., Chen, J., Hu, J., Peng, N., Guo, M., Jiang, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56703-2 · Cited by 28
Karlsson, C. A. Q., Järnum, S., Winstedt, L., Kjellman, C., Björck, L., Linder, A., & Malmström, J. A. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra117.000525 · Cited by 27
“Apart from implications as an important anti-phagocytic virulence factor (21), IdeS is being developed as a biopharmaceutical drug to temporarily remove pathogenic IgG in autoimmune conditions (22), and is also currently undergoing clinical trials in kidney transplant patients to evaluate its capacity to remove pathog…”
BackgroundSelf-citationB Cell Immunity in Lung Transplant Rejection - Effector Mechanisms and Therapeutic Implications
Ohm, B., & Jungraithmayr, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845867 · Cited by 31
“In kidney transplantation, IgG endopeptidase treatment successfully reduced DSA and allowed successful HLA-incompatible transplantation in highly sensitized recipients (97).”
Background
Metadata
- Authors
- Jordan, S. C., Lorant, T., Choi, J., Kjellman, C., Winstedt, L., Bengtsson, M., Zhang, X., Eich, T., Toyoda, M., Eriksson, B.-M., Ge, S., Peng, A., Järnum, S., Wood, K. J., Lundgren, T., Wennberg, L., Bäckman, L., Larsson, E., Villicana, R., Kahwaji, J., Louie, S., Kang, A., Haas, M., Nast, C., Vo, A., & Tufveson, G.
- Affiliations
- Uppsala University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-03
- Volume
- 377
- Issue
- 5
- Pages
- 442-453
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2740266422
- Cited by
- 377
- References
- 30
- Citations by year
- 2026: 32 · 2025: 44 · 2024: 37 · 2023: 50 · 2022: 45 · 2021: 39 · 2020: 38 · 2019: 45 · 2018: 36 · 2017: 11
- FWCI
- 30.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- ide, HLA sensitization, kidney transplantation, desensitization, donor-specific antibodies, antibody-mediated rejection, cold ischemia time, delayed graft function, adverse events, antibody rebound
- MeSH terms
- Adult, Antibodies, Bacterial Proteins, Cysteine Endopeptidases, Female, Histocompatibility Testing, HLA Antigens, Humans, Immunoglobulin G, Immunosuppression Therapy, Male, Middle Aged, Transplantation Immunology, Complement C1q, Kidney Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.